SK bioscience Secures FDA Approval for Phase 3 Clinical Trial of 21-Valent Pneumococcal Conjugate Vaccine in the U.S.
SK bioscience has taken a significant step towards entering the global pneumococcal market by receiving approval to proceed with the Phase 3 clinical trial of its 21-valent pneumococcal conjugate vaccine candidate in the United States, following earlier …